Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis

Chi Zhang,Long Shen,Ke-Jia Le,Mang-Mang Pan,Ling-Cong Kong,Zhi-Chun Gu,Hang Xu,Zhen Zhang,Wei-Hong Ge,Hou-Wen Lin
DOI: https://doi.org/10.3389/fcvm.2020.00151
IF: 3.6
2020-08-06
Frontiers in Cardiovascular Medicine
Abstract:<span><strong>Background:</strong> Emerging evidence shows that coronavirus disease 2019 (COVID-19) is commonly complicated by coagulopathy, and venous thromboembolism (VTE) is considered to be a potential cause of unexplained death. Information on the incidence of VTE in COVID-19 patients, however, remains unclear.<strong>Method:</strong> English-language databases (PubMed, Embase, Cochrane), Chinese-language databases (CNKI, VIP, WANFANG), and preprint platforms were searched to identify studies with data of VTE occurrence in hospitalized COVID-19 patients. Pooled incidence and relative risks (RRs) of VTE were estimated by a random-effects model. Variations were examined based on clinical manifestations of VTE (pulmonary embolism-PE and deep vein thrombosis-DVT), disease severity (severe patients and non-severe patients), and rate of pharmacologic thromboprophylaxis (≥60 and &lt;60%). Sensitivity analyses were conducted to strengthen the robustness of results. Meta-regression was performed to explore the risk factors associated with VTE in COVID-19 patients.<strong>Results:</strong> A total of 17 studies involving 1,913 hospitalized COVID-19 patients were included. The pooled incidence of VTE was 25% (95% CI, 19–31%; <i>I</i><sup>2</sup>, 95.7%), with a significant difference between the incidence of PE (19%; 95% CI, 13–25%; <i>I</i><sup>2</sup>, 93.2%) and DVT (7%; 95% CI, 4–10%<i>; I</i><sup>2</sup>, 88.3%; <i>P</i><sub><i>interaction</i></sub> &lt; 0.001). Higher incidence was observed in severe COVID-19 patients (35%; 95 CI%, 25–44%; <i>I</i><sup>2</sup>, 92.4%) than that in non-severe patients (6%; 95 CI%, 3–10%; <i>I</i><sup>2</sup>, 62.2%; <i>P</i><sub><i>interaction</i></sub> &lt; 0.001). The high rate of pharmacologic thromboprophylaxis in COVID-19 patients (≥60%) was associated with a lower incidence of VTE compared with the low pharmacologic thromboprophylaxis rate (&lt;60%) (19 vs. 40%; <i>P</i><sub><i>interaction</i></sub> = 0.052). Severe patients had a 3.76-fold increased risk of VTE compared with non-severe patients (RR, 4.76; 95% CI, 2.66–8.50; <i>I</i><sup>2</sup>, 47.0%). Sensitivity analyses confirmed the robustness of the primacy results.<strong>Conclusions:</strong> This meta-analysis revealed that the estimated VTE incidence was 25% in hospitalized COVID-19 patients. Higher incidence of VTE was observed in COVID-19 patients with a severe condition or with a low rate of pharmacologic thromboprophylaxis. Assessment of VTE risk is strongly recommended in COVID-19 patients, and effective measures of thromboprophylaxis should be taken in a timely manner for patients with high risk of VTE.</span>
cardiac & cardiovascular systems
What problem does this paper attempt to address?
The problem that this paper attempts to solve is about the incidence of venous thromboembolism (VTE) in hospitalized patients with Coronavirus Disease 2019 (COVID - 19). Specifically, the paper aims to comprehensively evaluate the VTE incidence in hospitalized COVID - 19 patients through systematic review and meta - analysis methods, and explore the effects of different clinical manifestations (such as pulmonary embolism (PE) and deep vein thrombosis (DVT)), disease severity (severe and non - severe patients), and pharmacological thromboprophylaxis (≥60% vs. <60%) on the VTE incidence. In addition, the study also attempts to explore potential factors related to VTE risk, in order to provide a basis for anticoagulation treatment decisions in COVID - 19 patients. The main conclusions of the paper are: - Combining data from 17 studies with a total of 1,913 hospitalized COVID - 19 patients, the overall incidence of VTE was 25% (95% CI, 19 - 31%; \(I^2\), 95.7%). - The incidence of pulmonary embolism (PE) was 19% (95% CI, 13 - 25%; \(I^2\), 93.2%), while the incidence of deep vein thrombosis (DVT) was 7% (95% CI, 4 - 10%; \(I^2\), 88.3%). - The VTE incidence in severe patients was significantly higher than that in non - severe patients (35% vs. 6%; \(P_{\text{interaction}}\) <0.001). - A high proportion of pharmacological thromboprophylaxis (≥60%) was associated with a lower VTE incidence (19% vs. 40%; \(P_{\text{interaction}}\) = 0.052). - The risk of VTE in severe patients was 3.76 times that in non - severe patients (relative risk (RR), 4.76; 95% CI, 2.66 - 8.50; \(I^2\), 47.0%). These findings emphasize the importance of evaluating VTE risk in COVID - 19 patients and suggest that effective anticoagulation measures should be taken in a timely manner for high - risk patients.